^
    1m
    Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (clinicaltrials.gov)
    P2, N=25, Not yet recruiting, Jennifer Woyach | Initiation date: May 2026 --> Sep 2026
    Trial initiation date
    |
    clonoSEQ®
    |
    Venclexta (venetoclax) • nemtabrutinib (MK-1026)
    1m
    Orelabrutinib Combined With Induction Therapy Followed by Sequential Monotherapy Maintenance in MCD Subtype Diffuse Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=66, Not yet recruiting, Ou Bai, MD/PHD
    New P2 trial
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine • prednisone • Inokai (orelabrutinib) • Polivy (polatuzumab vedotin-piiq) • thiotepa • Anruixi (zuberitamab)
    1m
    Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study. (PubMed, Blood Cancer J)
    ZR-CHOP demonstrates encouraging activity and acceptable safety in molecularly selected high-risk DLBCL, particularly in the MCD-like subgroup. (ClinicalTrials.gov number, NCT05290337).
    P2 data • Journal
    |
    TP53 (Tumor protein P53) • NOTCH1 (Notch 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD79B (CD79b Molecule)
    |
    TP53 mutation
    |
    Rituxan (rituximab) • Brukinsa (zanubrutinib)
    1m
    Economic Analysis of Alliance A041202 CLL Study (clinicaltrials.gov)
    P=N/A, N=55, Active, not recruiting, Canadian Cancer Trials Group | Trial completion date: Jun 2026 --> Dec 2026
    Trial completion date • HEOR
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • bendamustine
    1m
    Tazemetostat in Combination With Zanubrutinib and Anti-CD20 Monoclonal Antibody in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, University of Utah | Suspended --> Active, not recruiting
    Enrollment closed
    |
    Rituxan (rituximab) • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • Tazverik (tazemetostat)
    1m
    Focal adhesion kinase FAK interplays with ROR1 in the aggressiveness of chronic lymphocytic leukemia. (PubMed, BMC Med)
    Our findings reveal a reciprocal regulatory relationship between FAK and ROR1, with both proteins enriched in CLL cells that have exited the lymph nodes. Given defactinib's favorable safety profile in solid tumor trials, combining FAK inhibition with BTK inhibitors could enhance therapeutic efficacy by limiting leukemic clone adaptability and addressing resistance and relapse. While anti-ROR1 therapies showed limited efficacy as monotherapy in CLL trials, targeting multiple nodes of this regulatory network may prove more effective.
    Journal
    |
    CXCR4 (Chemokine (C-X-C motif) receptor 4) • ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1) • CD5 (CD5 Molecule) • LYN (LYN Proto-Oncogene Src Family Tyrosine Kinase) • ANXA5 (Annexin A5) • CTTN (Cortactin)
    |
    Imbruvica (ibrutinib) • Fakzynja (defactinib)
    1m
    Real-world clinical outcomes in patients with CLL previously treated with covalent BTKi and BCL2i regimens. (PubMed, Blood Neoplasia)
    Our results suggest an unmet need among patients with DR CLL. Future studies should continue to evaluate response durability with different treatments in DE and DR CLL populations.
    Clinical data • Journal • Real-world evidence
    |
    BCL2 (B-cell CLL/lymphoma 2)
    1m
    A Phase 2 Trial Of The Combination Of Zanubrutinib, Sonrotoclax, And Obinutuzumab For Patients With Treatment-Nave Chronic Lymphocytic Leukemia (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, M.D. Anderson Cancer Center
    New P2 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    clonoSEQ®
    |
    Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • Beqalzi (sonrotoclax)
    1m
    Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma (clinicaltrials.gov)
    P2, N=25, Not yet recruiting, Vanderbilt-Ingram Cancer Center
    New P2 trial
    |
    cyclophosphamide • Tecartus (brexucabtagene autoleucel) • nemtabrutinib (MK-1026)
    1m
    CaDAnCe-303: A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors (clinicaltrials.gov)
    P3, N=153, Active, not recruiting, BeOne Medicines | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Rituxan (rituximab) • bendamustine • catadegbrutinib (BGB-16673)
    1m
    Targeting Bruton tyrosine kinase with acalabrutinib attenuates murine sclerodermatous chronic graft versus host disease. (PubMed, Front Immunol)
    RNA-seq analysis of skin identified genes associated with keratinization that were downregulated with acalabrutinib treatment. Our results demonstrate that specific inhibition of BTK with acalabrutinib has a potentially beneficial role in ameliorating sclerodermatous cGVHD by improving the survival and clinical benefits and warrants further investigation in patients with cGVHD.
    Preclinical • Journal
    |
    BTK (Bruton Tyrosine Kinase) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • CXCL13 (Chemokine (C-X-C motif) ligand 13) • CCL2 (Chemokine (C-C motif) ligand 2) • CCL22 (C-C Motif Chemokine Ligand 22) • CCL3 (C-C Motif Chemokine Ligand 3)
    |
    Calquence (acalabrutinib)
    1m
    ARCHED: Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma (clinicaltrials.gov)
    P3, N=330, Recruiting, Universitt des Saarlandes | Trial primary completion date: Apr 2028 --> Feb 2029
    Trial primary completion date
    |
    ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6) • IRF4 (Interferon regulatory factor 4)
    |
    Rituxan (rituximab) • cyclophosphamide • Calquence (acalabrutinib) • vincristine • prednisolone